Vimarsana
Biggest News Aggregation in the World

Page 36 - Jack Weinstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jack Weinstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jack Weinstein Today - Breaking & Trending Today

Adhoc: Relief Therapeutics Holding SA: Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form - Vimarsana News

Adhoc: Relief Therapeutics Holding SA: Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form

Relief Therapeutics Holding SA / Key word(s): Patent Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent

Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Adm - Vimarsana News

Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Adm

Relief Therapeutics Holding SA / Key word(s): Patent08-Jul-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration...

Adhoc: Relief Therapeutics Holding SA: Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk - Vimarsana News

Adhoc: Relief Therapeutics Holding SA: Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk

Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil

Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk - Vimarsana News

Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk

Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk 04-Jul-2022 / 07:00 CET/CEST ...

Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission - Vimarsana News

Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission 04-Jul-2022